TriangleAnti-GARP Chimeric Antigen Receptor… (NCT06964737)
Anti-GARP Chimeric Antigen Receptor T Cel… trial for Recurrent Malignant Glioma (NCT06964737). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
When a high-grade glioma returns after standard treatment, there is no agreed next step. And the tumor walls itself off, releasing a signal, TGF-beta, that tells immune cells to stand down.
The idea: go after the protein that holds that signal on the cell surface.
It is called GARP; tumors with a lot of it do worse. A patient's own T cells are fitted with a receptor for it. At surgery, a small reservoir is placed under the scalp, and over five weeks the cells go straight into the cavity the tumor left.
In mice, the cells worked against several glioblastoma models without serious harm. This trial, at Ohio State with Brad Elder, asks first whether it is safe. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.